Literature DB >> 33553083

Patient Satisfaction With Medications for Opioid Use Disorder Treatment via Telemedicine: Brief Literature Review and Development of a New Assessment.

Thomas O Cole1, Darlene Robinson1, Andrea Kelley-Freeman2, Devang Gandhi1, Aaron D Greenblatt1, Eric Weintraub1, Annabelle M Belcher1.   

Abstract

Telemedicine is increasingly being used to treat patients with opioid use disorder (OUD). It has particular value in rural areas of the United States impacted by the opioid crisis as these areas have a shortage of trained addiction medicine providers. Patient satisfaction significantly impacts positive clinical outcomes in OUD treatment and thus is of great clinical interest. Yet little is known regarding patient satisfaction with the increasingly important platform of telemedicine-delivered medications for opioid use disorder (tMOUD). The goal of this review is to provide a summary of the existing literature regarding patient satisfaction with tMOUD. We also submit a novel survey based on an existing framework designed to assess tMOUD satisfaction, and present pilot data (N = 14) acquired from patients engaged in rural tMOUD care. Telemedicine provides a feasible method for delivering MOUD in rural areas, and our survey provides a useful assessment to measure patient satisfaction with tMOUD. In light of the pressing need for innovative and technology-driven solutions to the opioid epidemic (especially in light of the COVID-19 pandemic), future research should focus on the development and refinement of tools to assess the important implementation goal of patient satisfaction.
Copyright © 2021 Cole, Robinson, Kelley-Freeman, Gandhi, Greenblatt, Weintraub and Belcher.

Entities:  

Keywords:  buprenorphine; medication assisted treatment; opioid use disorder; patient satisfaction; rural; telebehavioral health; telemedicine

Mesh:

Substances:

Year:  2021        PMID: 33553083      PMCID: PMC7859509          DOI: 10.3389/fpubh.2020.557275

Source DB:  PubMed          Journal:  Front Public Health        ISSN: 2296-2565


  38 in total

1.  Does the use of telemental health alter the treatment experience? Inmates' perceptions of telemental health versus face-to-face treatment modalities.

Authors:  Robert D Morgan; Amber R Patrick; Philip R Magaletta
Journal:  J Consult Clin Psychol       Date:  2008-02

2.  Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Authors:  Roger A Rosenblatt; C Holly A Andrilla; Mary Catlin; Eric H Larson
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

Review 3.  Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.

Authors:  Hilary Smith Connery
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

4.  Opioid-related mortality in rural America: Geographic heterogeneity and intervention strategies.

Authors:  Khary K Rigg; Shannon M Monnat; Melody N Chavez
Journal:  Int J Drug Policy       Date:  2018-05-10

5.  Urban vs. rural differences in prescription opioid misuse among adults in the United States: informing region specific drug policies and interventions.

Authors:  Khary K Rigg; Shannon M Monnat
Journal:  Int J Drug Policy       Date:  2014-10-23

6.  Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis.

Authors:  Wanhong Zheng; Michael Nickasch; Laura Lander; Sijin Wen; Minchan Xiao; Patrick Marshalek; Ebony Dix; Carl Sullivan
Journal:  J Addict Med       Date:  2017 Mar/Apr       Impact factor: 3.702

7.  Satisfaction of forensic psychiatric patients with remote telepsychiatric evaluation.

Authors:  B B Brodey; K H Claypoole; J Motto; R G Arias; R Goss
Journal:  Psychiatr Serv       Date:  2000-10       Impact factor: 3.084

8.  Distance traveled and cross-state commuting to opioid treatment programs in the United States.

Authors:  Andrew Rosenblum; Charles M Cleland; Chunki Fong; Deborah J Kayman; Barbara Tempalski; Mark Parrino
Journal:  J Environ Public Health       Date:  2011-07-06

9.  A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence.

Authors:  Carla Dias Barbosa; Maria-Magdalena Balp; Károly Kulich; Nicola Germain; Diana Rofail
Journal:  Patient Prefer Adherence       Date:  2012-01-13       Impact factor: 2.711

10.  Opioid Policy Changes During the COVID-19 Pandemic - and Beyond.

Authors:  Corey S Davis; Elizabeth A Samuels
Journal:  J Addict Med       Date:  2020 Jul/Aug       Impact factor: 3.702

View more
  6 in total

1.  Virtual Behavioral Health Treatment Satisfaction and Outcomes Across Time.

Authors:  Mindy R Waite; Sara Diab; James Adefisoye
Journal:  J Patient Cent Res Rev       Date:  2022-07-18

Review 2.  Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.

Authors:  Hannah M Gregory; Veronica M Hill; Robert W Parker
Journal:  Cureus       Date:  2021-11-24

3.  A Buprenorphine Program Evaluation Before and During the COVID-19 Pandemic.

Authors:  Thomas M Hageman; Joshua Palmer; Prabir Mullick; Heeyoung Lee
Journal:  J Nurse Pract       Date:  2022-01-05       Impact factor: 0.767

Review 4.  Coronavirus Disease 2019 and the Impact on Substance Use Disorder Treatments.

Authors:  Osnat C Melamed; Wayne K deRuiter; Leslie Buckley; Peter Selby
Journal:  Psychiatr Clin North Am       Date:  2021-11-12

Review 5.  Digital Health Interventions for Delivery of Mental Health Care: Systematic and Comprehensive Meta-Review.

Authors:  Tristan J Philippe; Naureen Sikder; Anna Jackson; Maya E Koblanski; Eric Liow; Andreas Pilarinos; Krisztina Vasarhelyi
Journal:  JMIR Ment Health       Date:  2022-05-12

Review 6.  Telehealth-Based Delivery of Medication-Assisted Treatment for Opioid Use Disorder: a Critical Review of Recent Developments.

Authors:  Hossam Mahmoud; Hady Naal; Emile Whaibeh; Alyson Smith
Journal:  Curr Psychiatry Rep       Date:  2022-07-27       Impact factor: 8.081

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.